Haoru Wang, MD, Children’s Hospital of Chongqing Medical University, China
Dr Wang is a radiologist who focuses his research on the application of radiomics and deep learning based on medical imaging in differential diagnosis, prediction of the efficacy of neoadjuvant chemotherapy, risk stratification, and prognosis prediction of solid tumors. Additionally, he is interested in applying quantitative imaging parameters derived from functional magnetic resonance imaging and dual-energy computed tomography in solid tumors. Currently, he serves as an Editorial Board Member for BMC Medical Imaging.
Peng Xue, PhD, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Dr Peng Xue is a postdoctoral fellow at the School of Population Medicine and Public Health, Chinese Academy of Medical Sciences, and Peking Union Medical College. His research interests focus on digital health, cancer prevention, and evidence-based medicine. His key focus is developing and validating new AI technologies and strategies that may improve health outcomes. He is the principal investigator for several National postdoctoral science-funded grants and an Editorial Board Member for several BMC and Nature family journals.
Ravishankar Jayadevappa, PhD, MS, University of Pennsylvania, USA
Dr Jayadevappa is a Research Associate Professor of Medicine (primary) and Associate Professor of Urology (secondary). He is also a Senior Fellow at the Leonard Davis Institute of Health Economics, a Fellow of the Institute on Aging, a Member of Abramson Cancer Center, and a co-director of the urology health services research program. His research focuses on analyzing the tradeoffs among economic efficiency, equity, and quality. Dr Jayadevappa’s health services research interests are health policies for the elderly, health outcomes, quality of life, health disparities, and comparative effectiveness of chronic diseases such as prostate cancer, bladder cancer, lung cancer, breast cancer, OAB, congestive heart failure, and Alzheimer’s disease-related dementias. His research underscores his commitment to advancing the understanding of and improving outcomes of patients with cancer using novel artificial intelligence (AI), machine learning, and patient-centered outcomes research.
David-Dan Nguyen, MDCM, MPH, University of Toronto, Canada
Dr David-Dan Nguyen is a urology resident at the University of Toronto, Canada. He is also a doctoral student at the Institute of Health Policy, Management, and Evaluation of the University of Toronto. His doctoral work will focus on population-based risk stratification of prostate cancer patients using machine learning. Dr David-Dan obtained his medical degree from McGill University, and his master’s in public health degree from the Harvard T.H. Chan School of Public Health. While pursuing his MPH degree, he was a research fellow at the Center for Surgery and Public Health, Brigham and Women’s Hospital, USA.
